Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Summary not available.
Summary not available.
Summary not available.
Masimo (Nasdaq: MASI) agreed to be acquired by Danaher (NYSE: DHR) for $180.00 per share in cash, representing total consideration of $9.9 billion. The boards of both companies unanimously approved the transaction.
Masimo will operate as a standalone business unit and brand within Danaher’s Diagnostics segment and is expected to close in the second half of 2026, subject to regulatory approvals. Masimo will report Q4 and full‑year 2025 results on Feb 26, 2026 but will not host an earnings call.
Danaher (NYSE: DHR) entered a definitive agreement to acquire Masimo (NASDAQ: MASI) for $180 per share in cash, implying an approximate $9.9 billion enterprise value including assumed debt and net of cash. The deal values Masimo at ~18x estimated 2027 EBITDA (15x including expected synergies).
Danaher expects Masimo to generate >$530 million EBITDA in 2027, deliver >$125 million annual cost synergies and >$50 million annual revenue synergies by year five, and be accretive to adjusted diluted EPS by $0.15–$0.20 in year one and ~ $0.70 in year five. Closing is anticipated in H2 2026, subject to regulatory clearances and Masimo shareholder approval.
Masimo (NASDAQ: MASI) will report fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after market close on Thursday, February 26, 2026.
The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET, led by CEO Katie Szyman and CFO Micah Young. Registration is required for dial-in details; a replay will be archived on the company website.
Masimo (NASDAQ: MASI) provided preliminary fourth-quarter and full-year 2025 financial results ahead of its Feb 26, 2026 full release. Q4 revenue is expected to be approximately $411 million, about 12% reported growth (11% constant currency). Q4 non-GAAP EPS is expected to be more than $1.54, and shipments of noninvasive technology boards and instruments are about 69,000. For full-year 2025, revenue is expected at approximately $1,523 million (about 9% growth) with non-GAAP EPS >$5.55 (the high end of guidance) and shipments of ~270,000. Guidance includes the estimated impact of new tariffs, one additional calendar week, and adjustments for discontinued product lines and distribution model changes.
Masimo (NASDAQ: MASI) said its management will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific time.
A live webcast of the presentation will be available on the company website at www.masimo.com, and a replay will be posted following the live presentation.
Masimo (NASDAQ: MASI) hosted its 2025 Investor Day and published a multi-year strategic roadmap through 2028 focused on patient monitoring, technology innovation, and commercial execution.
Key long-range financial targets: Revenue CAGR of 7%–10% through 2028; operating margin ~30% by 2028; adjusted EPS $8.00 by 2028; and cumulative operating cash flow ≈ $1 billion from 2026–2028. Masimo also reaffirmed its 2025 non-GAAP guidance: revenue $1,510–$1,530 million; non-GAAP operating profit $412–$424 million; and non-GAAP diluted EPS $5.40–$5.55.
A replay of the Investor Day webcast is available via the company’s investor site.
Masimo (NASDAQ: MASI) won a patent infringement verdict against Apple after an eight-day jury trial in the U.S. District Court for the Central District of California, with the jury awarding $634,313,913 in damages and finding infringement on all asserted claims.
The case is part of a long-running, multi-venue dispute between the companies; Knobbe Martens led Masimo's trial team and has secured other wins for Masimo, including an import ban on infringing Apple Watches at the U.S. International Trade Commission in early 2024.